治疗耐药性NMDA受体通路的多基因评分与精神分裂症中大脑谷氨酸有关
Kira Griffiths1, Sophie E Smart2, Gareth J Barker3
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, UK; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
Schizophrenia research
|September 1, 2023
概括
NMDA受体基因的遗传变异与精神分裂症患者的前带皮质 (ACC) 中的谷氨酸水平降低有关,特别是那些有治疗耐药症状的人.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 精神病学是一个精神病学.
背景情况:
- 谷氨酸神经传递功能障碍与精神分裂症的病理生理学有关.
- NMDA受体的低功能可能是严重的基础,耐治疗的精神分裂症症状.
研究的目的:
- 研究NMDA受体通路多基因分数与精神分裂症皮质谷氨酸水平之间的关联.
- 为了确定这种关联是否在耐治疗和非耐治疗精神分裂症之间有所不同.
主要方法:
- 质子磁共振光谱 (1H-MRS) 测量了前带带皮层 (ACC) 谷氨酸在70名精神分裂症患者中.
- 通过使用NMDA受体基因内的遗传变异来构建NMDA受体通路多基因分数.
- 多基因分数由SNP与耐治疗和非耐治疗精神分裂症的关联加权.
主要成果:
- 较高的NMDA受体复杂通路多基因分数与精神分裂症中较低的ACC谷氨酸显著相关 (β = -0.25,p = 0.03).
- 这种关联是特定于多基因得分,由治疗耐药精神分裂症SNP关联加权.
- 当多基因评分被非耐治疗精神分裂症SNP协会加权时,没有发现有意义的关联 (β = 0.05,p = 0.79).
结论:
- 在NMDA受体基因中常见的遗传变异与精神分裂症中的ACC谷氨酸水平有关.
- 这种关系是针对耐治疗精神分裂症的,这表明它在严重的症状病理生理学中发挥了作用.
相关概念视频
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
740
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
740
Antiepileptic Drugs: Glutamate Antagonists
418
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
418
Drug Therapy
68
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
68
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Psychosis: Goals of Pharmacotherapy
165
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
165
Biological Causes of Schizophrenia
93
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
93


